Company profile: Cullinan Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage oncology therapeutics, including zipalertinib (CLN-081/TAS6417) for NSCLC with EGFR exon 20 insertion mutations in pivotal Phase 2b; CLN-619, an anti-MICA/B antibody tested with a checkpoint inhibitor for advanced solid tumors and multiple myeloma; CLN-049 for relapsed/refractory AML and MDS in Phase 1; and CLN-617, a collagen-binding IL-12/IL-2 fusion for advanced solid tumors, both as monotherapy and in combination with pembrolizumab.
Products and services
- Zipalertinib (CLN-081/TAS6417): Clinical-stage drug targeting non-small cell lung cancer with EGFR exon 20 insertion mutations, currently in pivotal Phase 2b trials
- CLN-049: Phase 1 therapeutic candidate for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes, currently in Phase 1 trials
- CLN-619: Combination-tested anti-MICA/B antibody evaluated with a checkpoint inhibitor for advanced solid tumors and multiple myeloma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cullinan Therapeutics
Rakuten Medical
HQ: United States
Website
- Description: Provider of investigational cancer therapies based on the proprietary Alluminox photoimmunotherapy platform, which combines a drug with targeting moieties and a light-activating device using non-thermal illumination to selectively target cancer cells; includes ASP-1929, an Alluminox-developed drug with dye-conjugated targeting moieties, approved in Japan for treating certain cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rakuten Medical company profile →
Xcell Biosciences
HQ: United States
Website
- Description: Provider of a next-generation development and manufacturing platform for enhanced cell therapy performance, offering AVATAR Foundry, an automated closed system for autologous cell therapy production (in beta); AVATAR System, an incubator that fine-tunes oxygen and pressure to mimic in vivo; AVATAR AI, software using machine learning for drug behavior prediction and potency assay development; and AVATAR AD, a four-instrument system for assay development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xcell Biosciences company profile →
Exact Sciences
HQ: United States
Website
- Description: Provider of cancer diagnostics, including Cologuard, a non-invasive at-home stool-based colorectal cancer screening test for individuals 45+, Riskguard hereditary cancer testing, Oncotype DX Breast Recurrence Score to assess recurrence and guide treatment for ER+/HER2- breast cancer, OncoExTra genomic profiling for therapy selection in advanced/metastatic cancer, and under-development Breast Radiation Score and colorectal cancer blood test.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exact Sciences company profile →
Algeta
HQ: Norway
Website
- Description: Provider of targeted oncology therapies based on an alpha-pharmaceutical platform, including radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algeta company profile →
Lytix Biopharma
HQ: Norway
Website
- Description: Provider of anti-microbials and cancer therapeutics, developing LTX-315, an oncolytic peptide for the treatment of solid tumors, currently in Phase II clinical trials for basal cell carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lytix Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cullinan Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cullinan Therapeutics
2.2 - Growth funds investing in similar companies to Cullinan Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cullinan Therapeutics
4.2 - Public trading comparable groups for Cullinan Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →